Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
17.08
+0.59 (3.58%)
At close: Apr 28, 2026, 4:00 PM EDT
17.08
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 30.5, with a low estimate of 26 and a high estimate of 36. The average target predicts an increase of 78.57% from the current stock price of 17.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 5 | 7 | 7 | 6 | 6 |
| Hold | 2 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 13 | 14 | 14 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +87.35% | Apr 27, 2026 |
| Needham | Needham | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +52.22% | Apr 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +87.35% | Apr 10, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +63.93% | Apr 9, 2026 |
| Needham | Needham | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +52.22% | Apr 8, 2026 |
Financial Forecast
Revenue This Year
57.30M
from 83.98M
Decreased by -31.77%
Revenue Next Year
84.83M
from 57.30M
Increased by 48.05%
EPS This Year
-3.11
from -3.05
EPS Next Year
-2.99
from -3.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 99.8M | 228.1M | ||||||
| Avg | 57.3M | 84.8M | ||||||
| Low | 39.5M | 41.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 18.8% | 298.0% | ||||||
| Avg | -31.8% | 48.1% | ||||||
| Low | -52.9% | -27.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.69 | -2.17 | ||||||
| Avg | -3.11 | -2.99 | ||||||
| Low | -3.64 | -3.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.